Macquarie Group’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-5,100
| Closed | -$83K | – | 2241 |
|
|
2022
Q3 | $83K | Sell |
5,100
-398
| -7% | -$4.63K | ﹤0.01% | 1817 |
|
|
2022
Q2 | $41K | Hold |
5,498
| – | – | ﹤0.01% | 2106 |
|
|
2022
Q1 | $50 | Hold |
5,498
| – | – | ﹤0.01% | 2145 |
|
|
2021
Q4 | $39K | Hold |
5,498
| – | – | ﹤0.01% | 2240 |
|
|
2021
Q3 | $63K | Sell |
5,498
-187,569
| -97% | -$2.74M | ﹤0.01% | 2153 |
|
|
2021
Q2 | $3.09M | Hold |
193,067
| – | – | ﹤0.01% | 1281 |
|
|
2021
Q1 | $3.45M | Buy |
193,067
+187,381
| +3,295% | +$3.24M | ﹤0.01% | 1008 |
|
|
2020
Q4 | $77K | Hold |
5,686
| – | – | ﹤0.01% | 1934 |
|
|
2020
Q3 | $67K | Hold |
5,686
| – | – | ﹤0.01% | 1884 |
|
|
2020
Q2 | $84K | Buy |
5,686
+586
| +11% | +$8.67K | ﹤0.01% | 1803 |
|
|
2020
Q1 | $69K | Hold |
5,100
| – | – | ﹤0.01% | 1747 |
|
|
2019
Q4 | $123K | Hold |
5,100
| – | – | ﹤0.01% | 1734 |
|
|
2019
Q3 | $98K | Hold |
5,100
| – | – | ﹤0.01% | 1745 |
|
|
2019
Q2 | $151K | Hold |
5,100
| – | – | ﹤0.01% | 1636 |
|
|
2019
Q1 | $242K | Sell |
5,100
-55,574
| -92% | -$2.45M | ﹤0.01% | 1425 |
|
|
2018
Q4 | $2.19M | Sell |
60,674
-20,000
| -25% | -$938K | ﹤0.01% | 945 |
|
|
2018
Q3 | $4.96M | Buy |
80,674
+6,641
| +9% | +$427K | 0.01% | 793 |
|
|
2018
Q2 | $5M | Buy |
74,033
+8,534
| +13% | +$477K | 0.01% | 779 |
|
|
2018
Q1 | $3.55M | Buy |
65,499
+12,879
| +24% | +$720K | 0.01% | 847 |
|
|
2017
Q4 | $3.14M | Buy |
52,620
+21,860
| +71% | +$1.33M | 0.01% | 901 |
|
|
2017
Q3 | $1.5M | Buy |
30,760
+19,160
| +165% | +$1.05M | ﹤0.01% | 1077 |
|
|
2017
Q2 | $610K | Buy |
+11,600
| New | +$540K | ﹤0.01% | 1272 |
|
|
2016
Q2 | – | Sell |
-46,889
| Closed | -$570K | – | 1655 |
|
|
2016
Q1 | $570K | Sell |
46,889
-5,452
| -10% | -$86.3K | ﹤0.01% | 1218 |
|
|
2015
Q4 | $1.27M | Sell |
52,341
-2,421
| -4% | -$56.5K | ﹤0.01% | 1034 |
|
|
2015
Q3 | $971K | Buy |
54,762
+13,329
| +32% | +$241K | ﹤0.01% | 1144 |
|
|
2015
Q2 | $731K | Buy |
41,433
+700
| +2% | +$12.8K | ﹤0.01% | 1236 |
|
|
2015
Q1 | $1.28M | Buy |
40,733
+6,200
| +18% | +$180K | ﹤0.01% | 1099 |
|
|
2014
Q4 | $1.01M | Buy |
34,533
+1,951
| +6% | +$49.5K | ﹤0.01% | 1162 |
|
|
2014
Q3 | $674K | Buy |
32,582
+19,606
| +151% | +$387K | ﹤0.01% | 1218 |
|
|
2014
Q2 | $321K | Buy |
+12,976
| New | +$225K | ﹤0.01% | 1373 |
|
Macquarie Group's AERI Position: Q4 2022 in Review
Macquarie Group sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 5,100 shares — an estimated $83K sold.
Macquarie Group first reported a position in AERI in Q2 2014 and held it in 30 quarters. The position peaked at $5M in Q2 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Macquarie Group reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Macquarie Group sold 5,100 Aerie Pharmaceuticals shares in Q4 2022, an estimated $83K.
- Macquarie Group first reported a position in Aerie Pharmaceuticals in Q2 2014 and held it in 30 quarters.
- Macquarie Group's Aerie Pharmaceuticals position peaked at $5M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.